This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dreses-Werringloer, U.
Right arrow Articles by Hudson, A. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dreses-Werringloer, U.
Right arrow Articles by Hudson, A. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2003, p. 2316-2318, Vol. 47, No. 7
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.7.2316-2318.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Detection of Nucleotide Variability in rpoB in both Rifampin-Sensitive and Rifampin-Resistant Strains of Chlamydia trachomatis

Ute Dreses-Werringloer,1 Ingrid Padubrin,2 Lars Köhler,2 and Alan P. Hudson1*

Department of Immunology and Microbiology, Wayne State University School of Medicine, Detroit, Michigan,1 Department of Internal Medicine, Division of Rheumatology, Medical School Hannover, Hannover, Germany2

Received 30 September 2002/ Returned for modification 17 January 2003/ Accepted 5 April 2003


arrow
ABSTRACT
 
A 656-bp PCR fragment from rpoB was sequenced from five rifampin-resistant Chlamydia trachomatis variants selected in vitro from a wild-type parent with a surprising level of genetic variability in this region. Three variants (MIC, 4 µg/ml) showed Ala522->Val in cluster I (codons 507 to 533), which harbors mutations in most rifampin-resistant bacteria. Two high-level resistance variants (MICs, 64 and 256 µg/ml) showed His526->Tyr in cluster I with additional genetic variation, some of which resulted in amino acid substitutions. None of the latter was situated in clusters related to rifampin resistance in other bacteria.


arrow
TEXT
 
Rifampin exerts its antibacterial effect through binding to the ß-subunit of bacterial RNA polymerase (RNAP). However, resistance to rifampin can develop rapidly and has been described for a number of bacteria, including Escherichia coli (11) and Mycobacterium tuberculosis (18-20). The primary mechanism of resistance is decreased binding capacity of RNAP for rifampin caused by nucleotide changes localized in the central region of the rpoB gene, specifying the ß subunit of the enzyme. Although there are three principal clusters harboring nucleotide changes (I to III, amino acid positions 507 to 533, 560 to 572, and 687, respectively), more than 90% of mutations are located in cluster I.

The obligate intracellular bacterial pathogen Chlamydia trachomatis is a major cause of urogenital and ocular infections worldwide. This organism has been shown to be highly sensitive to rifampin in susceptibility studies (e.g., references 4, 5, 7, 17, and 24). However, there are reports of emergence of resistance in in vitro systems (12, 13, 21). For Chlamydia, determinations of MIC for various antibiotics traditionally have been done by adding drug along with elementary bodies to permissive cells. However, this does not represent the in vivo situation, since antibiotics are used against Chlamydia only after intracellular infection has been established. We developed an in vitro cell culture model to investigate the long-term effect of antibiotics on established infection with C. trachomatis (serovar K) in epithelial cells (8). Briefly, antibiotic-free cultured HEp-2 cells were inoculated with C. trachomatis elementary bodies at a multiplicity of infection of 0.075. As previously reported, the effect of rifampin alone was investigated, as well as its combination with azithromycin (9). Treatment, starting 2 days after infection, was done with 0.015 µg of rifampin/ml, which is twofold higher than the MIC of 0.0075 µg/ml. Inhibition given by antichlamydial drugs was monitored in this system over a period of 20 days. Although rifampin alone generally proved able to both inhibit chlamydial growth and suppress de novo synthesis of bacterial rRNA, recurrent infection occasionally occurred in two independent experiments. In those instances, typical chlamydial inclusions were identified and we were able to recover infectious Chlamydia from the cultures. We prepared five variants that were clearly resistant, as determined by susceptibility testing. Three variants showed a MIC of 4 µg/ml, and the remaining two exhibited a higher level of resistance, with MICs of 64 and 256 µg/ml, respectively. Based on previous publications, we assumed that mutations in the rpoB gene would be responsible for the development of resistance to this drug in Chlamydia. We therefore prepared DNA from each of the five variants plus the original stock and amplified a 656-bp PCR product by using the primers rpoB-US 5'-GCGAATGGGCGATGAGAAGA-3' and rpoB-DS 5'-CCGTACTTGTGTCGGCTTCA-3'; these flank clusters I and II in the central portion of the rpoB gene. High Fidelity Taq polymerase (Invitrogen) was used to avoid amplification errors. The amplified PCR products were cloned into the pGEM-T Easy vector (Promega, Madison, Wis.) and were subsequently sequenced.

As a control for sequencing of the rifampin-resistant variants, the original susceptible strain was analyzed. Analysis of 20 independent clones revealed that the original stock comprised a genetically nonhomogeneous population (Table 1). Although 13 of 20 clone inserts showed 100% identity to the congruent nucleotide sequence region of C. trachomatis serovar D/UW-3/Cx (http://www.stdgen.lanl.gov), seven inserts contained base changes in the central region of rpoB. Three of those seven were silent; two of three inserts had two nucleotide changes each. The remaining four clone inserts carried base differences that resulted in amino acid changes; one clone harbored two such substitutions. No amino acid substitution was shown in either cluster I or II, known to be related to rifampin resistance. Four changes were located downstream of cluster II, whereas one was situated upstream of cluster I. A variety of amino acid substitutions was found, with changes of hydrophobic amino acids to other hydrophobic (Ala617->Val, Ile472->Val, and Ile587->Met), a change of Glu to basic Asp, and a change of polar Thr to Ala. The data suggest that more DNA sequence variation exists in the C. trachomatis genome than previously thought. The stock used in this study was obtained in 1989 (Washington Research Foundation, Seattle, Wash.), and it has been passed in culture since that time by a number of different people in the laboratory. Slightly differential handling of the stock over the years undoubtedly contributed to generation and/or maintenance of such genetic variability, since the original stock was not clonal. Importantly, culture conditions differ among the many laboratories that work with Chlamydia, and selective pressures exerted by such differing conditions over time would also lead to chlamydial populations that are nonhomogenous in nucleotide sequence.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Nucleotide variations identified in the rifampin-susceptible wild-type stock of C. trachomatis serovar K

Each of the five resistant variants carried an amino acid change in cluster I (Table 2). The three variants with a MIC of 4 µg/ml (1-3) each had a change at codon 522 (E. coli numbering system), which led to a change of Ala to Val. The remaining two variants (variants 4 and 5), each of which exhibited high-level rifampin resistance (MICs were 64 and 256 µg/ml, respectively), had a substitution of His526->Tyr. Both amino acid changes correspond to those known in other bacteria and have been shown to play a role in rifampin resistance. Substitutions at position 526 are among the most common in other bacteria, whereas changes at position 522 are less frequent but have been observed (1, 2, 11, 20, 23).


View this table:
[in this window]
[in a new window]
  		TABLE 2. Nucleotide differences identified in rifampin-resistant isolates of C. trachomatis

Eight cloned inserts were sequenced from strain 3, all of which showed precisely the same sequence in the 656-bp fragment. The high-resistance variants, i.e., variants 4 and 5, however, both represent a nonclonal population. Four clones of variant 4 and 3 clones from variant 5 harbored a second base change. Each of these was unique, and they were distributed over three different parts of the central region of the rpoB gene. These include the regions upstream of cluster I, between clusters I and II, and downstream of cluster II; none was identified in the known clusters related to rifampin resistance. One base change of each variant was silent. No systematic changes in the charge, polarity, or size of side groups was identifiable for the resulting amino acid substitutions. To our knowledge, no reports exist of genetic variations within one isolate of rifampin-resistant bacteria. Some publications have described double base changes in isolates of M. tuberculosis, Staphylococcus aureus, and Streptococcus pneumoniae (3, 10, 15, 16, 18, 22), all of which were found primarily in cluster I.

Although the number of resistant variants studied here is small, some correlation appears to exist between the level of resistance and the position of the nucleotide changes found in cluster I. The replacement of His526 with Tyr resulted in high-level resistance in variants 4 and 5, whereas substitutions at position 522 engendered lower MICs. These results are consistent with those from reports investigating rifampin resistance in E. coli and M. tuberculosis (11, 14, 18). Aubry-Damon et al. (1) reported some correlation not only with the position of the change but also with the nature of the new amino acid. The two clones of variant 5 harboring double base changes with resulting changes from Lys->Glu and Asp->Gly represent drastic alterations likely to result in conformational changes in the gene product. Structural studies with Thermotoga aquaticus demonstrate that the common amino acid substitutions in cluster I and II in rpoB do not occur at the active site of the enzyme and that most such changes comprise replacement of amino acids having small side chains by those having bulkier side chains (6). It is unclear what impact substitutions in other part of the ß subunit have on the binding of rifampin. The high-resistance Chlamydia variants, i.e., variants 4 and 5, harbored the same cluster I His526->Tyr change, but they differ by fourfold in their MIC, indicating that other mechanisms or other alterations in amino acid sequence in some other rpoB region contribute to resistance. None of the nucleotide changes in the parental strain were found in the resistant variants, which might suggest that the additional mutations found in variants 4 and 5 are responsible for the different levels of resistance.


arrow
ACKNOWLEDGMENTS
 
This work was supported by grant AR-42541 from the National Institutes of Health (A.P.H.) and grant 01VM9708/4 from the German Ministry of Technology, plus a supplemental grant from the Hannover Medical School (L.K.).


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Department of Immunology and Microbiology, Wayne State University School of Medicine, Gordon H. Scott Hall, 540 E. Canfield Ave., Detroit, MI 48201. Phone: (313) 993-6641. Fax: (313) 577-1155. E-mail: ahudson{at}med.wayne.edu. Back


arrow
REFERENCES
 
    1
  1. Aubry-Damon, H., C.-J. Soussy, and P. Courvalin. 1998. Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 42:2590-2594.[Abstract/Free Full Text]
    2. 2
  2. Aubry-Damon, H., M. Galimand, G. Gerbaud, and P. Courvalin. 2002. rpoB mutation conferring rifampin resistance in Streptococcus pyogenes. Antimicrob. Agents Chemother. 46:5171-5173.
    3. 3
  3. Bártfai, Z., Á. Somoskövi, C. Ködmön, N. Szabó, E. Puskás, L. Kosztolányi, E. Faragó, J. Mester, L. M. Parsons, and M. Salfinger. 2000. Molecular characterization of rifampin-resistant isolates of Mycobacterium tuberculosis from Hungary by DNA sequencing and the line probe assay. J. Clin. Microbiol. 39:3736-3739.
    4. 4
  4. Blackman, H. J., C. Yoneda, C. R. Dawson, and J. Schachter. 1977. Antibiotic susceptibility of Chlamydia trachomatis. Antimicrob. Agents Chemother. 12:673-677.[Abstract/Free Full Text]
    5. 5
  5. Bowie, W. R., C. K. Lee, and E. R. Alexander. 1978. Prediction of efficacy of antimicrobial agents in treatment of infections due to Chlamydia trachomatis. J. Infect. Dis. 138:655-659.[Medline]
    6. 6
  6. Campbell, E. A., N. Korzheva, A. Mustaev, K. Murakami, S. Nair, A. Goldfarb, S. A. Darst. 2001. Structural mechanism of rifampicin resistance of bacterial RNA polymerases. Cell 104:901-912.[CrossRef][Medline]
    7. 7
  7. Cevenini, R., M. P. Landini, M. Donati, and F. Rumpianesi. 1980. Antimicrobial drug susceptibility of 15 strains of Chlamydia trachomatis recently isolated from cases of non-gonococcal urethritis in Italy. J. Antimicrob. Chemother. 6:285-300.[Free Full Text]
    8. 8
  8. Dreses-Werringloer, U., I. Padubrin, B. Jürgens-Saathoff, A. P. Hudson, H. Zeidler, and L. Köhler. 2000. Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro. Antimicrob. Agents Chemother. 44:3288-3297.[Abstract/Free Full Text]
    9. 9
  9. Dreses-Werringloer, U., I. Padubrin, H. Zeidler, and L. Köhler. 2001. Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro. Antimicrob. Agents Chemother. 45:3001-3008.[Abstract/Free Full Text]
    10. 10
  10. Heep, M., B. Brandstätter, U. Rieger, N. Lehn, E. Richter, S. Rüsch-Gerdes, and S. Niemann. 2001. Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates. J. Clin. Microbiol. 39:107-110.[Abstract/Free Full Text]
    11. 11
  11. Jin, D. J., and C. A. Gross. 1988. Mapping and sequencing of mutations in the E. coli rpoB gene that lead to rifampicin resistance. J. Mol. Biol. 202:45-58.[CrossRef][Medline]
    12. 12
  12. Jones, R. B., G. L. Ridgeway, S. Bouling, and K. L. Hunley. 1983. In vitro activity of rifamycins alone and in combination with other antibiotics against Chlamydia trachomatis. Rev. Infect. Dis. 5(Suppl. 3):556-561.
    13. 13
  13. Keshishyan, H., L. Hanna, and E. Jawetz. 1973. Emergence of rifampin-resistance in Chlamydia trachomatis. Nature 244:173-174.[CrossRef][Medline]
    14. 14
  14. Ohno, H., H. Koga, S. Kohno, T. Tashiro, and K. Hara. 1996. Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob. Agents Chemother. 40:1053-1056.[Abstract]
    15. 15
  15. Padayachee, T., and K. P. Klugman. 1999. Molecular basis of rifampin resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:2361-2365.[Abstract/Free Full Text]
    16. 16
  16. Pozzi, G., M. Meloni, E. Iona, G. Orru, O. F. Thoresen, M. L. Ricci, M. R. Oggioni, L. Fattorini, and G. Orefici. 1999. rpoB mutations in multidrug-resistant strains of Mycobacterium tuberculosis isolated in Italy. J. Clin. Microbiol. 37:1197-1199.[Abstract/Free Full Text]
    17. 17
  17. Ridgeway, G. L., J. M. Owen, and J. D. Oriel. 1978. The antimicrobial susceptibility of Chlamydia trachomatis in cell culture. Br. J. Vener. Dis. 54:103-106.[Medline]
    18. 18
  18. Taniguchi, H., H. Aramaki, Y. Nikaido, Y., Mizuguchi, M. Nakamura, T. Koga, and S. Yoshida. 1996. Rifampin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis. FEMS Microbiol. Lett. 144:103-108.[CrossRef][Medline]
    19. 19
  19. Telenti, A., P. Imboden, F. Marchesi, D. Lowrie, S. Cole, M. J. Colston, L. Matter, K. Schopfer, and T. Bodmer. 1993. Detection of point mutations in the rpoB gene of rifampin-resistant mutations in Mycobacterium tuberculosis. Lancet 341:647-650.[CrossRef][Medline]
    20. 20
  20. Telenti, A., P. Imboden, F. Marchesi, T. Schmidheini, and T. Bodmer. 1993. Direct, automated detection of rifampin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis. Antimicrob. Agents Chemother. 37:2054-2058.[Abstract/Free Full Text]
    21. 21
  21. Treharne, J. D., P. J. Yearsley, and R. C. Ballard. 1989. In vitro studies of Chlamydia trachomatis susceptibility and resistance of rifampin and rifabutin. Antimicrob. Agents Chemother. 33:1393-1394.[Abstract/Free Full Text]
    22. 22
  22. Wichelhaus, T. A., V. Schäfer, V. Brade, and B. Böddinghaus. 1999. Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 43:2813-2816.[Abstract/Free Full Text]
    23. 23
  23. Williams, D. L., C. Waguespack, K. Eisenach, J. T. Crawford, F. Portaels, M. Salfinger, C. M. Nolan, C. Abe, V. Sticht-Groh, and T. P. Gillis. 1994. Characterization of rifampin resistance in pathogenic mycobacteria. Antimicrob. Agents Chemother. 38:2380-2386.[Abstract/Free Full Text]
    24. 24
  24. Zanetti, S., D. Usai, A. Nonis, and G. Fadda. 1996. In vitro activity of 3-azinomethyl-rifamycin (SPA-S-565) against Chlamydia trachomatis. J. Antimicrob. Chemother. 37:357-359.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, July 2003, p. 2316-2318, Vol. 47, No. 7
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.7.2316-2318.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • O'Connor, J. R., Galang, M. A., Sambol, S. P., Hecht, D. W., Vedantam, G., Gerding, D. N., Johnson, S. (2008). Rifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficile. Antimicrob. Agents Chemother. 52: 2813-2817 [Abstract] [Full Text]  
  • Rupp, J., Solbach, W., Gieffers, J. (2008). Variation in the mutation frequency determining quinolone resistance in Chlamydia trachomatis serovars L2 and D. J Antimicrob Chemother 61: 91-94 [Abstract] [Full Text]  
  • Murphy, C. K., Mullin, S., Osburne, M. S., van Duzer, J., Siedlecki, J., Yu, X., Kerstein, K., Cynamon, M., Rothstein, D. M. (2006). In Vitro Activity of Novel Rifamycins against Rifamycin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 50: 827-834 [Abstract] [Full Text]  
  • Xia, M., Suchland, R. J., Carswell, J. A., Van Duzer, J., Buxton, D. K., Brown, K., Rothstein, D. M., Stamm, W. E. (2005). Activities of Rifamycin Derivatives against Wild-Type and rpoB Mutants of Chlamydia trachomatis. Antimicrob. Agents Chemother. 49: 3974-3976 [Abstract] [Full Text]  
  • Binet, R., Maurelli, A. T. (2005). Frequency of Spontaneous Mutations That Confer Antibiotic Resistance in Chlamydia spp.. Antimicrob. Agents Chemother. 49: 2865-2873 [Abstract] [Full Text]  
  • Siewert, K., Rupp, J., Klinger, M., Solbach, W., Gieffers, J. (2005). Growth Cycle-Dependent Pharmacodynamics of Antichlamydial Drugs. Antimicrob. Agents Chemother. 49: 1852-1856 [Abstract] [Full Text]  
  • Kutlin, A., Kohlhoff, S., Roblin, P., Hammerschlag, M. R., Riska, P. (2005). Emergence of Resistance to Rifampin and Rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis. Antimicrob. Agents Chemother. 49: 903-907 [Abstract] [Full Text]  
  • Suchland, R. J., Bourillon, A., Denamur, E., Stamm, W. E., Rothstein, D. M. (2005). Rifampin-Resistant RNA Polymerase Mutants of Chlamydia trachomatis Remain Susceptible to the Ansamycin Rifalazil. Antimicrob. Agents Chemother. 49: 1120-1126 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dreses-Werringloer, U.
Right arrow Articles by Hudson, A. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dreses-Werringloer, U.
Right arrow Articles by Hudson, A. P.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»